Market Overview

St. Jude Medical, Inc. (STJ) Maintains An Accumulate Rating


Analysts Brooke E. West and John D. Crowther at Craig-Hallum Capital Group LLC have maintained an Accumulate rating for St. Jude Medical, Inc. (NYSE: STJ). Analysts have also maintained the price target of $41 for St. Jude Medical, Inc.

The management at St. Jude has reiterated its guidance of 7%-11% growth in sales, and 12%-14% growth in EPS in 2010. According to analysts, this would require the company to have a growth at or above market rates for all business segments.

Analysts expect the company to maintain share in its four markets. However, analysts believe that the company will struggle to achieve even the low-end of its sales guidance range for 2010 as it is heavily weighted towards significant growth in the back half of the year, a reacceleration of the US CRM business, and share gains in A-Fib.


Related Articles (STJ)

View Comments and Join the Discussion!

Posted-In: Brooke E. West Craig-Hallum Capital Group LLC John D. CrowtherAnalyst Color News Guidance Markets Analyst Ratings

Need corporate guidance data?
Click here to see licensing options.

Latest Ratings

MAXRJP MorganDowngrades55.0
BNFTRaymond JamesDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at